In summary, future studies need to focus on exploring the relationship between different types of U2AF1 mutations and the clinical characteristics and prognosis of MDS and AML patients to more accurately guide disease risk stratification and prognosis assessment. This evidence concerns the gene U2AF1 and myelodysplastic syndrome.